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ABSTRACT 
Training for accurate image interpretation is essential for the clinical use of β-amyloid positron 
emission tomography (PET) imaging, but the role of reader training and the accuracy of the 
algorithm for routine visual assessment of florbetaben PET scans are unclear. The aim of this 
study was to test the robustness of the visual assessment method for florbetaben scans, 
comparing efficacy readouts across different readers and training methods, and against a 
histopathology standard of truth (SoT). 
METHODS: Analysis was based on data from an international open-label, non-randomized, 
multicenter Phase 3 study in patients with or without dementia (ClinicalTrials.gov: 
NCT01020838). Florbetaben scans were assessed visually and quantitatively, and results were 
compared with amyloid plaque scores. For visual assessment, either in-person training (n=3 
expert readers) or an electronic training method (n=5 naïve readers) was used. Brain samples 
from participants who died during the study were used to determine the histopathological SoT 
using Bielschowsky silver staining (BSS) and immunohistochemistry for β-amyloid plaques. 
RESULTS: Data were available from 82 patients who died and underwent post-mortem 
histopathology. Comparing visual assessment results with BSS+immunohistochemistry as SoT, 
median sensitivity was 98.2% for the in-person trained readers and 96.4% for the e-trained 
readers, while median specificity was 92.3% and 88.5%, respectively. Median accuracy was 
95.1% and 91.5%, respectively. Based on BSS only as the SoT, median sensitivity was 98.1% 
and 96.2%, respectively, median specificity was 80.0% and 76.7%, and median accuracy was 
91.5% and 86.6%. Inter-reader agreement (Fleiss’ kappa) was excellent (0.89) for in-person-
trained readers and very good (0.71) for e-trained readers. Median intra-reader agreement was 
0.9 for both in-person and e-trained readers. Visual and quantitative assessments were 
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concordant in 88.9% of scans for in-person trained readers and in 87.7% of scans for e-trained 
readers.  
CONCLUSION: Visual assessment of florbetaben images was robust in challenging scans from 
elderly end-of-life individuals. Sensitivity, specificity, and inter-reader agreement were high, 
independent of expertise and training method. Visual assessment was accurate and reliable for 
detection of plaques using BSS and immunohistochemistry, and well correlated with quantitative 
assessments. 
Key words: Alzheimer’s disease, florbetaben, positron-emission tomography 
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INTRODUCTION 
Florbetaben is an 18F-labeled β-amyloid tracer developed for positron emission tomography 
(PET). In 2014, florbetaben was approved by the US Food and Drug Administration, the 
European Medicines Agency and the Korean Ministry of Food and Drug Safety (MFDS) to 
detect or exclude the presence of neuritic β-amyloid plaques in brain (1,2). In a Phase III study, 
high sensitivity and specificity were demonstrated for florbetaben in the detection of β-amyloid 
aggregates comparing PET with post-mortem histopathology (3). 
The current clinical method for interpretation of florbetaben β-amyloid PET scans is 
visual assessment (4). Training for accurate image interpretation is a key issue for β-amyloid 
PET imaging – all readers require training and several different training tools are available. The 
type of reader training and the accuracy for visual assessment of florbetaben PET scans are 
unclear. In order to test the adequacy of the training comparing visual assessment against β-
amyloid histopathology, scans from end-of-life patients are required. It is known that pronounced 
atrophy and other brain abnormalities can compromise image interpretation in end-of-life 
individuals. Indeed, severe structural brain abnormalities were present in the participants in the 
histopathology cohort, leading to challenging scans. If acceptable images can be obtained under 
these conditions, improved reads can be expected in the clinical setting with less technically 
challenging scans. Moreover, a technically difficult dataset would be likely to expose differences 
between training approaches (electronic training tool vs. in-person trainer) that might inform best 
training practices. 
The aim of the present study was to test the robustness of the visual assessment method 
for florbetaben scans, comparing efficacy readouts (sensitivity, specificity, and kappa values) 
across different readers and training methods, against a histopathology standard of truth (SoT) in 
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end-of-life patients. The study also compared visual and quantitative assessments of florbetaben 
PET, since quantification is commonly used in research and may be implemented in future 
clinical routine. 
MATERIALS AND METHODS 
Study design and population 
This analysis was based on an international open-label, non-randomized, multicenter 
Phase 3 study (ClinicalTrials.gov: NCT01020838). The study was conducted in accordance with 
the Declaration of Helsinki, and approvals from regulatory authorities and ethics committees 
were obtained. 
Participants were recruited from 15 centers (including dementia clinics with brain-bank 
experience, hospices, private practices, and dementia self-help groups) in Australia, Europe, 
Asia, and North America, and examined between February 2010 and August 2013. Eligible 
subjects were non-demented individuals, n=9, and patients with Alzheimer’s disease (AD), n=60, 
dementia with Lewy bodies (DLB), n=4, or other dementias, n=9. Key exclusion criteria were 
cerebral large-vessel disease, brain tumors, and cardiovascular instability requiring intensive care 
or therapeutic intervention. All participants (or their legal representatives) provided written 
informed consent to undergo brain MRI, a PET scan with florbetaben, and to donate their brain 
for post-mortem examination. Details of the study methods have been presented previously (3). 
Brain Image Data Acquisition 
PET images were acquired 90–110 minutes after intravenous injection of 300 MBq ± 
20% florbetaben (5) according to a standardized acquisition and image-processing protocol 
established during a technical visit to each center. Three-dimensional volumetric T1-weighted 
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brain MRI (e.g. magnetization prepared rapid gradient echo or spoiled gradient recalled 
sequences) were collected.  
Study design  
Florbetaben scans were assessed visually and quantitatively, and results compared with β-
amyloid presence/absence in pathology. For visual assessment, either in-person training (n=3 
expert readers) or an electronic training (e-training) method (n=5 naïve readers) was used. 
Composite standardized uptake value ratios (SUVRs) were determined (6), and receiver 
operating characteristic curve analysis used to ascertain the optimal threshold for the 
sensitivity/specificity calculations. The composite SUVR providing the highest sum of 
sensitivity and specificity was selected as cut-off value. 
Visual assessment method 
The in-person expert training and electronic training modules were identical in approach 
and content (6,7). The training emphasized normal white matter anatomy using structural MRI 
and coregistered florbetaben PET images to appreciate white matter - gray matter boundaries 
since a positive scan demonstrates extension of radiotracer uptake beyond the cortical white 
matter to adjacent gray matter in key brain regions. Specifically, readers used a regional cortical 
tracer uptake scoring system (RCTU) (1 = no tracer uptake, 2 = moderate tracer uptake, 3 = 
pronounced tracer uptake) in four brain areas: lateral temporal cortex, frontal cortex, posterior 
cingulate cortex/precuneus, parietal cortex (see figure 1 for details). The resulting scores 
condense into a binary interpretation (score 1 = negative; score 2 or 3 = positive). A RCTU score 
of 1 in each brain region led to a brain amyloid plaque load (BAPL) score of 1, a RCTU score of 
2 in any brain region and no score 3 led to a BAPL score of 2. A RCTU score of 3 in any of the 4 
brain regions led to a BAPL of 3. 
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No access to other scan orientations (i.e. coronal, sagittal), and no reorientation or 
structural information from computed tomography (CT) or magnetic resonance imaging (MRI) 
was available to readers. Readers viewed scans in gray scale only. There were some minor 
differences between the training, as the trainees could not ask questions of an expert reader 
during the review with the electronic training tool.  
All images were assessed by eight readers: three in-person trained experts and five naïve 
readers trained using an e-training tool. All readers were nuclear medicine physicians. The 
”expert reader” was defined as having direct experience with PET amyloid scans. The naïve 
reader had no experience with the visual assessment method and was not involved in any pivotal 
study using an 18F-labeled amyloid imaging agent. 
Quantitative assessment method 
Brain PET image quantification was performed using a standardized volume of interest 
template applied to the spatially normalized grey matter PET image based on a 
gray/white/cerebrospinal fluid segmentation of the participant’s T1-weighted volumetric MRI 
(6). A region of interest template (6) sampled the lateral temporal, frontal, anterior and posterior 
cingulate gyrus/precuneus, and parietal lobes which were averaged to determine a composite 
SUVRs calculated using the cerebellar cortex as the reference tissue. 81 of the 82 brains were 
evaluated in this fashion; in one scan the segmentation process failed owing to poor technical 
quality of the MRI. 
Pathology standard of truth 
Brain samples from 82 participants who died during the study were used to determine the 
histopathological SoT. Six brain regions were examined with both Bielschowsky silver staining 
(BSS) and immunohistochemistry for the β-amyloidprotein: middle frontal gyrus, occipital 
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cortex, hippocampus/parahippocampal gyrus, anterior cingulate cortex, posterior cingulate 
cortex/precuneus, and cerebellar cortex.  
The presence of amyloid plaques was assessed by a blinded histopathology consensus 
panel of three expert neuropathologists using two different methods: Bielschowsky silver 
staining (BSS) and immunohistochemistry for β-amyloidFor the analysis presented here only 
neuritic plaques and cored plaques were considered. Neuritic plaque density (as detected by 
BSS) was assessed according to the Consortium for Establishing a Registry for Alzheimer 
Disease (CERAD) criteria  (8), providing a semi-quantitative score with the categories “absent”, 
“sparse”, “moderate”, or “frequent”.  The same semi-quantitative categories were used to score 
the number of cored plaques detected by β-amyloidimmunohistochemistry. β-amyloid was 
regarded as present in a given brain region when sufficient neuritic or cored plaques were present 
to achieve a score of “moderate” or “frequent”. 
Importantly, BSS is not specific for β-amyloid deposits and also has some technical 
limitations that may hinder the identification of some neuritic plaques in AD (9). The 
combination of BSS and immunohistochemistry for β-amyloid is recommended in current 
neuropathologic guidelines for assessment of AD pathology (10,11).  Therefore, both BSS and 
BSS+immunohistochemistry data were used for further analyses. 
Statistical analysis 
Sensitivity, specificity and accuracy were evaluated by comparing visual assessments 
with the histopathological SoT. Independent Mann-Whitney tests were performed to compare the 
reported parameters between training groups. Reliability of visual assessment was evaluated by 
Cohens’ and Fleiss’ kappa. To investigate the intra-reader agreement, a random subsample of 
images (22 for the in-person trained group and 20 for the e-trained) was re-read by all readers. 
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The association between quantitative and visual assessments was evaluated with a Chi squared 
test. 
RESULTS 
Study population and post-mortem β-amyloid histopathology 
In total, 205 end-of-life individuals underwent florbetaben PET imaging (52% male; 
mean age, 76.9 ± 11 [range, 48–98] years). As of August 2013, 82 participants had died and 
undergone autopsy and post-mortem histopathology (clinical diagnoses: AD, n=60; DLB, n=4; 
other dementias, n=9; non-demented, n=9). Comparison of clinical diagnosis of AD and β-
amyloid pathology (BSS+immunohistochemistry as SoT) revealed a discordance in some 
patients with AD, with 13 of the 60 patients with a clinical diagnosis of probable AD were found 
to be β-amyloid negative. Of the four subjects with DLB as clinical diagnosis, two were β-
amyloid positive. Seven of the nine subjects clinically classified as other dementia were β-
amyloid negative. 4 of the 9 non-demented healthy elderly subjects were β-amyloid positive. In 
total, of the 82 brains examined by histopathology, 56 were β-amyloid positive and 26 were β-
amyloid negative with BSS+immunohistochemistry as SoT. Using BSS alone, 52 brains were β-
amyloid positive and 30 β-amyloid negative. 
Sensitivity and specificity of the visual assessment 
Of the 82 PET scans assessed in this study, 81 were classified equally by both training 
groups. With BSS+immunohistochemistry as SoT, a median (range) sensitivity of 98.2% (94.6–
98.2%) was obtained for the three in-person trained readers and 96.4% (91.1–100%) for the five 
e-trained readers. With BSS alone, median (range) sensitivity was 98.1% (96.2–98.1) and 96.2% 
(90.4–100%), respectively (Table 1). With BSS+immunohistochemistry, median (range) 
specificity was 92.3% (88.5–92.3%) for the in-person trained readers and 88.5% (53.9–92.3%) 
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for the e-trained readers, whereas BSS alone led to 80.0% (76.7–83.3%) and 76.7% (46.7–80%), 
respectively (Table 1). Median (range) accuracy with BSS+immunohistochemistry was 95.1% 
(93.9–96.3%) for in-person trained readers and 91.5% (84.1–93.9%) for e-trained readers. BSS 
alone as SoT had a median accuracy of 91.5% (90.2–91.5%) for in-person trained readers and 
86.6% (79.3–89%) for e-trained readers (Table 1). Independent Mann-Whitney tests were 
performed to compare the reported parameters between training groups. No statistical differences 
were found for sensitivity and specificity, independent of the SoT. Accuracy was higher for 
expert in-person trained readers than for the e-trained readers (p=0.03) (Table 1). Individual 
reader results of visual assessments are provided in supplementary Table 1. 
Inter- and intra-reader agreement 
Inter-reader agreement (Fleiss’ kappa) was 0.89 (considered excellent, 95% confidence 
interval [CI]: 0.82, 0.97) for expert in-person-trained readers and 0.71 (considered very good, 
95% CI: 0.62, 0.81) for naïve e-trained readers (Table 2). Median (range) intra-reader agreement 
was 0.9 (0.79–0.90) for expert in-person trained readers and 0.9 (0.66–1.00) for e-trained readers 
(Table 3). 
Comparison of visual and quantitative assessments 
81 of 82 images were evaluated with both quantitative and visual methods by the in-
person trained readers and e-trained readers. Receiver operating characteristic curve analysis of 
composite grey matter SUVRs resulted in an optimal cut-off of 1.47 with  a sensitivity of 85.7% 
(95% CI, 73.8–93.6%) and a specificity of 92.0% (95% CI, 74.0–99.0%.  87.7% (n=71) of the 
scans were classified as positive or negative by both the e-trained readers and quantitative 
approaches, with the remaining 12.3% (n=10) of scans showing a discrepancy between the two 
approaches. Both methods (visual assessment by five e-trained readers and SUVR quantification) 
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were significantly and strongly related (Χ2=44.19, p<0.0001, Kappa = 0.73; Table 4, Figure 2A). 
Similarly, for in-person trained readers; 88.9% (n=72) of assessments were concordant and 
11.1% (n=9) were discordant with quantitation, with significant relationship between methods 
(Χ2 = 47.33, p<0.0001, Kappa = 0.76; Table 5, Figure 2B). 
Further details of the 10 discordant cases are summarized in Table 6. Concordance with 
the pathology results was found with visual assessment in 9 cases by in-person trained readers, in 
8 cases by e-trained readers, but with the quantitative assessment only 2 cases matched the 
pathology results.  Marked atrophy was found in 7 cases, all with visual assessment matching 
pathology results (6 positive and one negative case). However, for the 7 marked atrophy cases 
none of the quantitative assessment results matched with pathology, showing SUVRs < 1.47 in 
the 6 positive cases and SUVR of 1.52 in the negative case with marked atrophy. Reader 
agreement for 8 of 10 cases was very high both for the in-person and electronically trained reader 
groups. Only for one subject (case # 75 in table 6, supplementary table 1) the visual assessments 
did differ for the two methods. 
Challenging cases 
The patient cohort included challenging cases, such as subjects with marked brain 
atrophy or scans with head motion. Figure 3 shows sample florbetaben PET scans from a patient 
with marked brain atrophy, with potential for false-positive assessment. A small percentage of 
scans demonstrated motion as illustrated in Figure 4. 
DISCUSSION 
Results from this study demonstrate high sensitivity and specificity of florbetaben PET 
imaging for evaluation of β-amyloid plaques in end-of-life individuals. Importantly, the 
sensitivity and specificity were independent of the read training method, the previous expertise 
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of readers in β-amyloid PET scan assessment, and the histopathology method used (BSS with or 
without immunohistochemistry). However, specificity increased for BSS+immunohistochemistry 
compared with BSS alone, as four brains in the BSS+immunohistochemistry group were 
additionally categorized as β-amyloid positive. Indeed, BSS+immunohistochemistry is 
recommended in current neuropathological guidelines for assessment of AD pathology (10,11). 
Intra-reader and inter-reader agreement was very high for both training groups. 
The individual differences in sensitivity and specificity amongst the five inexperienced 
readers are particularly informative. There was a wide range of specificity in particular, with two 
readers showing relatively lower performance than the other three. Post-study interviews with 
each individual reader suggested that those with poorer performance were less rigid in the 
application of the training rules to their visual assessments. Specifically, when assessing whether 
a particular region is positive, the algorithm requires that the majority (i.e. at least 50%) of the 
axial slices comprising each region must be positive. In some instances, the poorer readers did 
not apply this rule systematically, leading to a region being classified as positive. Nonetheless, 
the sensitivity and specificity in the present study were consistent with earlier analyses from the 
same study (3) and also with previous reports using florbetaben PET  (6,12) using clinical 
diagnosis as the SoT. Pathology examinations have shown, however, that clinical diagnosis of 
AD can be wrong (i.e. individuals diagnosed with AD dementia who do not show β-amyloid 
plaques upon autopsy) in 10–30 % of cases (13). This can lead to false-negatives compromising 
the sensitivity estimation when using clinical diagnosis as SoT. 
The relationship of visual reads to quantitative values was also consistent with prior 
reports (6,14), indicating high concordance between visual positivity and negativity and the 
composite SUVR using a quantitative cut-off for positive and negative scans. There were only 
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few cases (10 for e-trained and 9 for in-person trained out of 81 case evaluations) in which there 
was discordance between visual and quantitative assessments. The visual assessment method 
used did not allow comparison of the PET scan images with CT or MR. This may lead to 
difficulties in the interpretation of some cases with atrophy, and quantification could potentially 
help here. Most of the visual vs quantitative discordant cases showed marked atrophy. However, 
in this study the visual assessment of discordant cases matched with pathology results. 
Quantitative assessment of cases with marked atrophy were all discordant with pathology results. 
The readers were more adept at distinguishing gray matter from white matter uptake in scans 
with severe atrophic changes than the quantification method. Two exceptions to this are shown 
in figures 1 and 2 in the supplementary material. This suggests that atrophy may affect the 
quantification method used in this study more than the visual assessment. Further investigation is 
required to substantiate this and whether partial volume error correction influences this result. 
The end-of-life population used in this study is not the intended population for β-amyloid 
PET scanning. The clinically intended population will likely have less structural brain 
abnormalities observed in this study cohort. Furthermore, the reading methodology designed for 
florbetaben in the present study was quite restrictive, with readers not permitted to use all the 
tools routinely available in nuclear medicine for PET assessment (3). In clinical practice, PET 
scans are read using three spatial orientations, with structural images provided by CT or MRI to 
guide anatomical localization of findings, often in discontinuous color scales for fused images. 
Additional use of all available tools for image reading will likely increase the diagnostic 
performance. Nevertheless, excellent results were obtained even allowing for the challenging 
nature of some scans and the stringent requirements of the applied reading methodology. 
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CONCLUSION 
Overall, visual assessment of florbetaben images was robust even in challenging scans 
from elderly end-of-life individuals. Sensitivity and specificity were high, as was inter-reader 
agreement, independent of the reader expertise and training method employed. The visual 
assessment strategy and respective training tools to analyze florbetaben PET scans are accurate 
and reliable in the detection of brain neuritic β-amyloid plaques as assessed using BSS, and 
cored plaques as assessed using immunohistochemistry, and showed a good correlation with 
quantitative assessments. 
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Figure 1. Visual patterns of abnormality and normality taught to readers using an electronic 
training tool or during in-person training. Cerebellum: A contrast between the white matter 
(arrows) and grey matter is seen in both negative and positive scans. Extracerebral tracer uptake 
in scalp and in the posterior sagittal sinus (arrowhead) can be seen. Lateral temporal lobes: The 
positive scan shows a “plumped”, smooth appearance of the outer border of the brain (dashed 
line) from tracer uptake in the grey matter. Spiculated or “mountainous” appearance of the white 
matter (arrows) characterizes the negative scan. Frontal lobes: The positive scan shows the 
tracer uptake has a “plumped”, smooth appearance due to the grey matter signal (dashed line). 
Spiculated appearance of the white matter in the frontal lobes (arrows) is seen in the negative 
scan. Posterior cingulate / precuneus: Adjacent to the splenium (arrow), the region appear as a 
hypo-intense “hole” (circle) in the negative scan, whereas this hole is absent (circle) in the 
positive scan. Parietal lobes: In the positive scan, the midline between the parietal lobes is 
thinner. The cortical areas are “filled-up” and show smoother appearance as the uptake extends 
to the outer rim. In the negative scan, the midline between the parietal lobes can be easily 
identified (long arrow); white matter has spiculated appearance (short arrow) with less uptake to 
the outer rim (dashed line).  
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Figure 2. Comparison of visual and quantitative image assessment. Visually assessed images 
were based on the majority results classified into V+ (visual positive scan) and V- (visual 
negative scan). Assessment data is plotted related to composite SUVR and subject age (years). 
A) Depicts the majority read data of the electronically trained readers and, B) shows majority
read data of the in-person trained readers.  
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Figure 3. Florbetaben a) PET and b) MRI scans from patient # 71 with marked brain atrophy, 
which was assessed by all readers as β-amyloid positive. The patient was found to be β-amyloid 
negative on post-mortem histopathology and positive in the quantitative assessment (SUVR = 
1.53). 
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Figure 4. Florbetaben a) PET and b) MRI scans from patient # 68 with motion artifact, 
potentially leading to a false-positive visual assessment. All readers assessed the scans as β-
amyloid negative. The patient was found to be β-amyloid negative on post-mortem 
histopathology and negative on the quantitative assessment (SUVR = 1.10). 
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Table 1. Sensitivity, specificity and accuracy of visual florbetaben PET scan reads in the eight 
readers (n=82 scans).  
BSS  BSS /IHC 
Rea
der 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Accuracy   
(95% CI) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Accuracy   
(95% CI) 
In‐
perso
n 
traini
ng 
1  96.2 (90.9‐100.0) 
83.3 (70.0‐
96.7) 
91.5 (85.4‐
97.5) 
94.6 (88.7‐
100.0) 
92.3 (82.1‐
100.0) 
93.9 (88.7‐
99.1) 
2  98.1 (94.3‐100.0) 
76.7 (61.5‐
91.8) 
90.2 (83.8‐
96.7) 
98.2 (94.7‐
100.0) 
88.5 (76.2‐
100.0) 
95.1 (90.5‐
99.8) 
3  98.1 (94.3‐100.0) 
80.0 (65.7‐
94.3) 
91.5 (85.4‐
97.5) 
98.2 (94.7‐
100.0) 
92.3 (82.1‐
100.0) 
96.3 (92.3‐
100.0) 
Electr
onic 
medi
a 
traini
ng 
1  94.2 (87.9‐100.0) 
80.0 (65.7‐
94.3) 
89.0 (82.3‐
95.8) 
92.9 (86.1‐
99.6) 
88.5 (76.2‐
100.0) 
91.5 (85.4‐
97.5) 
2  98.1 (94.3‐100.0) 
46.7 (28.8‐
64.5) 
79.3 (70.5‐
88.0) 
98.2 (94.7‐
100.0) 
53.8 (34.7‐
73.0) 
84.1 (76.2‐
92.1) 
3  90.4 (82.4‐98.4) 
80.0 (65.7‐
94.3) 
86.6 (79.2‐
94.0) 
91.1 (83.6‐
98.5) 
92.3 (82.1‐
100.0) 
91.5 (85.4‐
97.5) 
4  96.2 (90.9‐100.0) 
76.7 (61.5‐
91.8) 
89.0 (82.3‐
95.8) 
96.4 (91.6‐
100.0) 
88.5 (76.2‐
100.0) 
93.9 (88.7‐
99.1) 
5  100.0  56.7‐ (38.9‐74.4) 
84.1‐ (76.2‐
92.1)  100.0 
65.4 (47.1‐
83.7) 
89.0 (82.3‐
95.8) 
Statis
tics 
p‐
valu
e 
0.64  0.28  0.03  0.76  0.21  0.05 
 BSS = Bielschowsky silver staining; IHC = immunohistochemistry; Statistics = Independent Mann-
Whitney tests 
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Table 2. Inter-reader Cohen’s kappa values* (95% confidence intervals) 
In-person training Electronic media training 
In-
person 
1 2 3 
Electronic 
media 
1 2 3 4 5 
1 x 
0.93 
(0.85–
0.89 
(0.79–
1 x 
0.57 
(0.38–
0.87  
(0.76–
0.91  
(0.82–
0.63  
(0.45–
2  x 
0.86 
(0.75–
2  x 
0.53  
(0.34–
0.66  
(0.48–
0.75  
(0.59–
3 x 3 x
0.86  
(0.76–
0.58  
(0.41–
4 x
0.71  
(0.56–
5 x
*Kappa values in the range 0.81–1.00 are considered excellent, 0.61–0.80 very good, and 0.41–0.60
moderate
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Table 3. Intra-reader Cohens’ kappa values 
Reader Cohen’s kappa (and 95% CI)
In-person Training (n=22) 1 0.90 (0.72 - 1.00) 
2 0.90 (0.71 - 1.00) 
3 0.79 (0.51 - 1.00) 
Electronic media Training (n=20) 1 1.00 (1.00 - 1.00) 
2 0.66 (0.30 - 1.00) 
3 0.90 (0.71 - 1.00) 
4 0.90 (0.70 - 1.00) 
5 1.00 (1.00 - 1.00) 
CI = confidence interval 
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Table 4. Electronically trained visual assessment in comparison to composite SUVR 
quantification. 
Quantitative assessment
Positive Negative Total
Visual assessment 
Positive 48 8 56
Negative 2 23 25
Total 50 31 81 
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Table 5. In-person visual assessment in comparison to composite SUVR quantification. 
Quantitative assessment
Positive Negative Total
Visual assessment 
Positive 48 7 55
Negative 2 24 26
Total 50 31 81
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Table 6. Comparison of visual versus (semi)quantitative analysis for discordant cases (i.e. cases visually read as positive but 
quantified as negative or visually read as negative and quantified as positive). 
Case Age Visual in-person trained Visual e-trained 
Quanti-
fication SUVR PET evaluation 
Histopathology
(BSS+IHC) Clinical diagnosis 
 Agreement  Agreement
3 82 positive 100% positive 100% negative 1.01 Marked atrophy positive AD 
5 90 positive 100% positive 100% negative 1.02 Marked atrophy positive AD 
39 82 positive 100% positive 100% negative 1.42 Marked atrophy positive AD 
40 70 positive 100% positive 100% negative 1.14 --- positive Other dementia
43 92 positive 100% positive 80% negative 1.18 Marked atrophy positive AD 
44 72 positive 100% positive 100% negative 1.14 Marked atrophy positive AD 
45 91 positive 100% positive 100% negative 1.45 Marked atrophy positive AD 
75 81 negative 67% positive 80% negative 1.17 --- negative AD 
22 98 negative 67% negative 80% positive 1.67 --- positive AD 
67 83 negative 100% negative 80% positive 1.52 Marked atrophy negative Other dementia 
AD = Alzheimer’s disease, Agreement = Inter-reader agreement within training group, PET evaluation = additional PET assessment conducted 
after initial study.  
